An engineered virus kills cancer cells more effectively than another virus currently used in treatments, according to Hokkaido University researchers.
Hokkaido University researchers have engineered a virus that selectively targets and kills cancer cells. The virus, called dl355, has an even stronger anticancer effect than another engineered virus currently used in clinical practice, according to a study published in the journal Oncology Reports.
Molecular oncologist Fumihiro Higashino and colleagues deleted a gene involved in viral replication, called E4orf6, from a type of adenovirus. The team previously discovered that E4orf6 stabilizes a type of mRNA called ARE-mRNAs in the infected cells enabling viral replication. ARE-mRNAs are known to be stable in stressed cells and cancer cells, but rapidly degrade in normal cells.
In laboratory tests, they found that their modified adenovirus, called dl355, replicated and increased its number significantly more in cancer cells than it did in normal cells. Higashino explains “The E4orf6-lacking virus relies on the stable ARE-mRNAs in cancer cells for its replication.”
Some viruses can be used to treat cancers, as they replicate within the cells until they burst and die. The researchers infected several types of cultured cancer cells with 100 dl355 virus particles per cell and found that nearly all the cancer cells died within seven days. In contrast, most normal cells infected with the virus did not die, even after seven days. Several cancer cell lines managed to survive low doses of dl355, but all cancer cells were killed by the virus as the dose was increased. Tumour growth was also significantly suppressed when dl355 was administered to human tumour cells grown in mice.
Finally, the team compared the anticancer effects of dl355 with another anticancer adenovirus currently used in clinical practice, called dl1520. dl355 replication was higher in all cancer cell lines tested, including cervical and lung cancer cells, and was better at killing all but one type of cancer cell, compared to dl1520. Both viruses only killed very few normal cells.
The findings suggest that dl355 has potential to be an effective anticancer treatment, the team concludes. They suggest enhancing the stabilization of ARE-mRNAs in cancer cells could even further strengthen its effect, but Professor Higashino notes that further research is required. “While we think dl355 has the potential to be an effective treatment method in dealing with many types of cancers, much more research needs to be done. When we think of a timeline, at least five more years of further research may be required, possible more, on top of clinical trials,” Professor Higashino noted.
Learn more: Engineering a cancer-fighting virus
The Latest on: Engineered virus
via Google News
The Latest on: Engineered virus
- New Virus Variant May Be Somewhat Deadlier, U.K. Warnson January 22, 2021 at 2:49 pm
The evidence on the fatality rate is worrisome but not yet solid, scientists said. It contrasts with news that Britain is vaccinating its people at a promising pace.
- Covid vaccines: what are the implications of new variants of virus?on January 22, 2021 at 1:43 pm
In common with others, the virus that causes Covid-19 mutates as it spreads. Most mutations have little or no effect, but some can change the behaviour of the virus. Mutations in a variant found in ...
- Fauci warns COVID-19 mutations could lead to faster virus spreadon January 21, 2021 at 2:29 pm
Dr. Anthony Fauci on Thursday said that new mutations of COVID-19 are not likely to considerably decrease the effectiveness of vaccines but could lead to a faster spread of the virus.
- Can the COVID-19 Vaccine Beat the Proliferation of New Virus Mutations?on January 20, 2021 at 5:41 pm
Stopping transmission blocks the opportunity for viral mutation. Vaccination is the only means we have of standing in the virus’s way.
- COVID SCIENCE-S. African virus variant may resist antibody drugs; Pfizer/BioNTech vaccine seems to work vs UK varianton January 20, 2021 at 5:05 pm
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
- Iraqis Flout Virus Precautions Amid Widespread Belief in Immunityon January 20, 2021 at 7:40 am
Even some Iraqi health officials are promoting the false idea that Iraq has acquired herd immunity. Scientists say that Iraq could be in for a major new outbreak.
- Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumorson January 19, 2021 at 3:30 am
Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
- DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilitieson January 19, 2021 at 3:00 am
DiNAQOR, a gene therapy platform company, today announced that it has acquired EHT Technologies GmbH, a Germany-based engineered heart ...
- The best way to kill a superbug? Weaponise a viruson January 19, 2021 at 12:07 am
With the medical world struggling to treat antibiotic-resistant infections, could scientists turn to a group of viruses that explode bacterial cells from within?
- Orion Engineered Carbons Donates $10,000 to Memorial Health System of Ohio for COVID-19 Reliefon January 18, 2021 at 10:00 am
Orion Engineered Carbons S.A. (NYSE: OEC), a worldwide supplier of specialty and high-performance carbon black with a facility in Belpre, Ohio, today ...
via Bing News